Voyager Therapeutics announces updates from phase 1b trial of VY-AADC01
Voyager announced updates regarding the Phase 1b trial of VY-AADC01 for patients with advanced Parkinson’s disease. The Phase 1b trial remains on track to deliver six-month safety, motor function, and biomarker data from Cohort 3, and longer-term safety and motor function data in mid-2017. January 20, 2017